Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24912840 | 0.90 | HTR7 (0.35) | ESR1KCNH2CYP3A4 | |
| SCHEMBL27152115 | 0.90 | HTR7 (0.35) | ESR1KCNH2CYP3A4 | |
| SCHEMBL26084330 | 0.88 | STS (0.39) | ESR1KCNH2CYP3A4 | |
| SCHEMBL23127014 | 0.86 | ESR1 (0.39) | ESR1KCNH2CYP3A4 | |
| SCHEMBL24162533 | 0.86 | CARM1 (0.37) | ESR1KCNH2CYP3A4 | |
| SCHEMBL23127017 | 0.85 | ESR1 (0.37) | ESR1KCNH2CYP3A4 | |
| SCHEMBL24178254 | 0.85 | ESR1 (0.33) | ESR1KCNH2 | |
| SCHEMBL23127029 | 0.83 | ESR1 (0.40) | ESR1KCNH2CYP3A4 | |
| SCHEMBL25002312 | 0.82 | ESR1 (0.43) | ESR1KCNH2CYP3A4 | |
| SCHEMBL23127071 | 0.81 | ESR1 (0.36) | ESR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008798-A1 | PALLADIUM CATALYZED SYNTHESIS OF AMINOALDEHYDE INTERMEDIATES | HOFFMANN-LA ROCHE INC. (US) | 2026-01-08 | — | — | US | disclosed |
| CN-119907798-A | Novel substituted 2,3,4, 9-tetrahydro-1H-pyrido [3,4-B ] indolecarboxylic acid derivatives, process for their preparation and their therapeutic use | 赛诺菲 | 2025-04-29 | — | — | CN | disclosed |
| US-20240409535-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | GENENTECH, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240317738-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | GENENTECH, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| CN-118515596-A | Solid forms and methods of making fused tricyclic compounds, including methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-112437685-B | Solid forms and methods of making fused tricyclic compounds, including methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| CN-118239948-A | Solid forms and methods of making fused tricyclic compounds, including methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023284837-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 四川海思科制药有限公司 | 2023-01-19 | — | — | WO | disclosed |
| CN-115611895-A | Arylamino derivative estrogen receptor modulators and uses thereof | 四川海思科制药有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220041587-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | HOFFMANN-LA ROCHE INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220002304-A1 | PROCESSES FOR MAKING SERD TRICYCLIC COMPOUNDS HAVING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY | GENENTECH, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| WO-2021213358-A1 | BORON-CONTAINING COMPOUNDS AND APPLICATION THEREOF | 江苏先声药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021213358-A1 | BORON-CONTAINING COMPOUNDS AND APPLICATION THEREOF | 江苏先声药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| EP-3810283-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | F. Hoffmann-La Roche AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| US-10954234-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | GENENTECH, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954234-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | GENENTECH, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| CN-112437685-A | Solid forms of 3- ((1R,3R) -1- (2, 6-difluoro-4- ((1- (3-fluoropropyl) azetidin-3-yl) amino) phenyl) -3-methyl-1, 3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indol-2-yl) -2, 2-difluoropropan-1-ol and methods of making fused tricyclic compounds containing a substituted phenyl or pyridinyl moiety, including methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | GPER1, ESR1, ESRRA | ESR1 2/4885KCNH2 3514/4885CYP3A4 189/4885 |
| US-20260008798-A1 | PALLADIUM CATALYZED SYNTHESIS OF AMINOALDEHYDE INTERMEDIATES | ADH1C, AOC1, AOC2 | ESR1 4822/4885KCNH2 485/4885CYP3A4 3031/4885 |
| US-20220002304-A1 | PROCESSES FOR MAKING SERD TRICYCLIC COMPOUNDS HAVING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY | PLK2, CHEK1, PLK4 | ESR1 478/4885KCNH2 4270/4885CYP3A4 4/4885 |
| US-20240409535-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | TP53, DPYD, FLI1 | ESR1 2780/4885KCNH2 2316/4885CYP3A4 116/4885 |
| US-20240317738-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | TP53, DPYD, FLI1 | ESR1 2780/4885KCNH2 2316/4885CYP3A4 116/4885 |
| US-20220041587-A1 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE | TP53, DPYD, FLI1 | ESR1 2780/4885KCNH2 2316/4885CYP3A4 116/4885 |
| US-10954234-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | TP53, DPYD, FLI1 | ESR1 2780/4885KCNH2 2316/4885CYP3A4 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.